Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.
You may also be interested in...
R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.
The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.
AstraZeneca and Merck & Co hope Lynparza will soon have a third treatment indication after their PARP inhibitor became the first to demonstrate a benefit in germline BRCA-mutated metastatic pancreatic cancer, having hit targets in the Phase III POLO trial.